SEPTIN9 and acute myeloid leukemia: Patient ALMA_11_BM and PB (13-39 years, male; coverage 17.30x BM, 24.62x PB), diagnosed with relapsed refractory MLL-positive AML, was accurately classified as AML with t(v;11q23); KMT2A-r in both tissues, corroborated by genomic detection of KMT2A-SEPTIN9 bidirectional fusion (Fig. 6d).